CIK 0001668243
- Non-accelerated filer
- Smaller reporting company
UroGen Pharma Ltd.
Sign in to watch- Ticker
- URGN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- Operating
- Phone
- +972 97707601
- Business address
- 9 HA'TA'ASIYA ST, RA'ANANA, Israel, 4365007
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $182,793
- in 3 filings
Net −$182,793. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-06-04 | Schoenberg Mark Chief Medical Officer | Exercise or conversion | +1,042 | 5,652 | ||
| 2019-06-04 | Schoenberg Mark Chief Medical Officer | Shares withheld for taxes | −343 | $35.05 | $12K | 5,309 |
| 2019-06-04 | Schoenberg Mark Chief Medical Officer | Exercise or conversion · Restricted Stock Units (RSUs) | −1,042 | 6,250 | ||
| 2019-06-03 | Tomasello Shawn Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-06-03 | FALBERG KATHRYN E Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-06-03 | BUTITTA CYNTHIA M Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-06-03 | Cohen Fred E Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-06-03 | Nussbaum Ran Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-06-03 | Holden Stuart Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-06-03 | Belldegrun Arie Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2019-05-14 | Mullennix Stephen Chief Operating Officer | Exercise or conversion | +1,759 | 5,989 | ||
| 2019-05-14 | Mullennix Stephen Chief Operating Officer | Sale | −608 | $37.98 | $23K | 5,381 |
| 2019-05-14 | Mullennix Stephen Chief Operating Officer | Exercise or conversion · Restricted Stock Units | −1,759 | 12,314 | ||
| 2019-03-27 | Belldegrun Arie Director | Exercise or conversion | +128,000 | $4.02 | $515K | 212,211 |
| 2019-03-27 | Belldegrun Arie Director | Exercise or conversion · Stock Option (right to buy | −128,000 | $4.02 | $515K | 0 |
| 2019-03-21 | Schoenberg Mark Chief Medical Officer | Purchase | +272 | $37.01 | $10K | 4,610 |
Page 25 of 25 · 496 trades